Why the study?
Many heart failure patients have HFpEF and face a shortage of effective therapeutic strategies, prompting review of emerging interatrial septal connection devices.
Do interatrial septal connection devices provide a favorable efficacy and safety profile in patients with HFpEF?
Do interatrial septal connection devices provide a favorable efficacy and safety profile in patients with HFpEF?
Interatrial septal connection devices represent an emerging mechanical strategy with a favorable initial efficacy and safety profile for patients with HFpEF, though long-term data are needed.
Interatrial septal devices may offer a mechanical option for HFpEF; leaves open efficacy confirmation in randomized trials.
Heart failure (HF) affects an increasing number of geriatric patients. The condition is classified according to whether the left ventricular ejection fraction (EF) is reduced or preserved. Many patients have heart failure with preserved ejection fraction (HFpEF) and face a shortage of effective therapeutic strategies. However, an emerging mechanical strategy for treatment is gaining momentum. Interatrial septal connection devices, i.e. V-wave device and Interatrial septal device, are new devices for patients with heart failure with preserved ejection fraction. We review the function of these systems and the data from the recent clinical trials. Interatrial septal connection device therapy provided favorable efficacy and safety profile applicable to a wide range of patients with HFpEF. However, the long-term effects of these devices on morbidity.
No takes yet. Share an insight, caveat, or question.
Al‐Sadawi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: